BMEA Biomea Fusion, Inc.

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.

$6.63
As of 01/27/2022     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/16/2021
Outstanding shares:  29,044,784
Average volume:  220,456
Market cap:   $211,446,028
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BNKF6N0

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   1.01
PS ratio:   0.00
Return on equity:   -15.87%
Net income %:   0.00%